New drug cocktail aims to tame transplant complication

NCT ID NCT07285889

Recruiting now Disease control Sponsor: First Affiliated Hospital of Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called gecacitinib (jaktinib) combined with steroids as a first treatment for acute graft-versus-host disease (GVHD), a serious complication after stem cell transplants. About 35 adults who have had a stem cell transplant and develop moderate to severe GVHD will receive the drug combo. The goal is to find the safest and most effective dose and see how well it controls the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: gecacitinib (also known as jaktinib) combined with glucocorticoids (steroids)
What this could lead to: If it works, this could point toward a more effective first-line treatment for acute graft-versus-host disease, potentially improving outcomes for stem cell transplant patients.
What could go wrong: This is an early-phase trial with only 35 participants, so results may not apply to everyone. The drug combination may cause side effects or fail to control the disease better than current treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE GRAFT VERSUS HOST DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute graft versus host disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE GRAFT VERSUS HOST DISEASE

Contacts and locations

Locations

The First Affiliated Hospital, Zhejiang University School of Medicine.
RECRUITING

Hangzhou, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.